medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2009, Número 1

<< Anterior Siguiente >>

Acta Med 2009; 7 (1)


Demencias valoradas con tomografía por emisión de positrones y 18F-fluordesoxiglucosa

Altamirano LJ, Estrada G

Idioma: Español
Referencias bibliográficas: 50
Paginas: 29-41
Archivo PDF: 273.19 Kb.


RESUMEN

Introducción: La PET-FDG es la técnica reina de la medicina nuclear, con la cual obtenemos mapas numéricos de la actividad metabólica del cerebro humano “in vivo”. Comentaremos las aplicaciones clínicas de la fluordesoxiglucosa. Objetivo: Exponer a los médicos relacionados con la neurología las aplicaciones clínicas de un estudio metabólico con un análogo de la glucosa en distintos tipos de demencias. Técnica: El paciente amerita de 4-6 horas de ayuno y abstenerse de tomar café, té, alcohol, no fumar y con glucemia normal. La 18F-FDG, tiene una vida media de 110 minutos y se administra por vía intravenosa a razón de 1.0 - 2.5 MBq/kg. Al cabo de 30-60 minutos se adquieren las imágenes. Con cámaras de última generación y modo 3D, la adquisición suele durar 20 minutos. Conclusiones: Incluyendo esta nueva tecnología ya disponible en nuestro país en el algoritmo diagnóstico de las enfermedades del sistema nervioso central, se puede modificar el panorama diagnóstico de las enfermedades mentales en etapas más tempranas, pudiendo administrar con mayor certeza y precozmente un tratamiento específico, mejorando el pronóstico, la calidad de vida, la actividad laboral y la relación social y familiar de los enfermos, reduciendo costos e incapacidades.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Brownell GL. A history of positron imaging. Http://www.mit.edu/-glb/nodel.html- nodell.html.glbr@shore.net 1999: 10-15.

  2. Carreras DLJ, Lapeña GL, Asencio BC et al. PET en Oncología. Ed. Nova Sidonia. Primera edición. Madrid. 2002; 7(45): 293-310.

  3. Koeppe RA, Gilman S, Joshi A, Liu S, Little R et al. 11C-DTBZ and 18FDG PET measures in differentiating dementias. J Nucl Med 2005; 46(6): 936-44.

  4. Dager SR, Friedman SD. Brain imaging and the effects of caffeine and nicotine. Annals of Medicine 2000; 32: 592-599.

  5. Bagary M, Fluck E, File SE, Joyce E, Lockwood G, Grasby P. Is benzodiazepine-induced amnesia due to deactivation of the left prefrontal cortex? Psychopharmacology (Berl) 2000; 150: 292-299.

  6. Agencia de Evaluación de Tecnologías sanitarias (AETS). Instituto de Salud Carlos II-Ministerio de Sanidad y Consumo. Tomografía por emisión de positrones en fluordeoxiglucosa (FDG-PET) en Neurología. Madrid AETS-Instituto de Salud Carlos III, Junio de 1999.

  7. Salud mental, demencias y trastornos asociados. Secretaría de Salud. México. Primera edición. 2002: 17-58.

  8. Silverman DH, Small JW, Chang SY, Lu CS, Kung, Mk et al. Positron emission tomography in evaluation of dementia. Regional brain metabolism and long term outcome. JAMA 2001; 286: 2120-27.

  9. Newberg AB, Alavi A. The role of imaging in the management of patients with central nervous systems disorders. Radiol Clin N Am 2005; 43: 49-65.

  10. Silverman DH. Brain 18FDG PET in diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluation. Nuclear imaging. J Nucl Med 2004; 45: 594-607.

  11. Desai AK, Grossberg. Diagnosis and treatment of Alzheimer disease. Neurology 2005; 64: S34-39.

  12. Mosconi L, Pupi A, De Cristoforo TR, Falla M, Sorbi S, Herholz K. Functional interaction of the entorinal cortex: a 18FDG PET study on normal aging and Alzheimer disease. J Nucl Med 2004; 45: 382-92.

  13. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer´s disease. Ann Nucl Med 2001; 15: 85-92.

  14. Silverman DH, GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286: 2120-7.

  15. Alexander GE, Furey ML, Grady CL, Pietrini P, Brady DR, Mentis MJ et al. Association of premorbid intellectual function with cerebral metabolism in Alzheimer´s implications for cognitive reserve hypothesis. Am J Psychiatry 1997; 152: 165-72.

  16. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer´s disease. J Nucl Med 2002; 43: 21-6.

  17. Minoshima S, Giordani B, Berent S et al. Metabolic reduction in the posterior cingulated cortex in very early Alzheimer´s disease. Ann Neurol 1997; 42: 85-94.

  18. Kuhl DE, Small GW, Riege WH et al. Cerebral metabolic patterns before the diagnosis of probable Alzheimer´s disease (abstract). J Cereb Blood Flow Metab 1987; 7 (suppl): S406.

  19. Frazekas F, Alavi A, Chawluk JB et al. Comparison of CT, MR and PET in Alzheimer´s dementia and normal aging. J Nucl Med 1989; 30: 1607-15.

  20. De Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-71.

  21. Guze BH, Baxter Jr LR, Schwartz JM, Szuba MP, Mazziotta JC, Phelps ME. Changes in glucose metabolism in dementia of the Alzheimer type compared with depression: a preliminary report. Psychiatr Res 1991; 40: 195-202.

  22. Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, De Leon MJ. 18F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer’s disease. J Nucl Med 2007; 48: 1129-1134.

  23. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 2008; 49: 390-398.

  24. Ng S, Villemagne VL, Berlangieri S, Sze-Ting L, Cherk M, Gong SJ et al. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer’s disease. J Nucl Med 2007; 48: 547-552.

  25. Esposito G, Giovacchini G, Jeih-San L, Bhattacharjee AK, Greenstein D, Schapiro M et al. Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J Nucl Med 2008; 49 (9): 1414-1421.

  26. Benson DR, Kuhl DE, Hawkins RA et al. The fluorodeoxyglucose 18F scan in Alzheimer´s disease and multi-infarct dementia. Arch Neurol 1983; 40: 771-740.

  27. Sabri O, Hellwig D, Schreckenberger M, Cremerius U, Schneider R, Kaiser HJ et al. Correlation of neuropsychological, morphological and functional (regional cerebral blood flow and glucose utilization) findings in cerebral microangiopathy. J Nucl Med 1998; 39: 147-154.

  28. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J et al. Transplantation of cultured neuronal cells for patients with stroke. Neurology 2000; 55: 565-569.

  29. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer´s disease and vascular dementia. J Neural Transm Suppl 1998; 53: 237-50.

  30. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998; 39: 1875-1878.

  31. Jeong Y, Chos SS, Park JM, Kang SJ, Lee JS et at. 18FDG PET findings in frontotemporal dementia: and SPM analysis of 29 patients. J Nucl Med 2005; 46: 233-39.

  32. Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005; 4: 701-80.

  33. Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with Lewy bodies and those with mild Alzheimer’s disease. J Nucl Med 2007; 48: 704-711.

  34. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer´s disease. Neurology 1998; 51: 125-130.

  35. McKeith IG, Tizson BW, Lowe J, Emre, Obrien JT et at. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005; 65: 1863-72.

  36. Mayeux R, Chen J, Mirabello E et al. An estimate of the prevalence of dementia in idiopathic Parkinson´s disease. Neurology 1990; 40: 1513-7.

  37. 37.Kuhl DE, Metter JE, Benson FD et al. Similarities of cerebral glucose metabolism in Alzheimer´s and Parkinsonian dementia. J Cereb Blood Flow Metab 1985; 5: 169-170.

  38. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ et al. Cortical dysfunction in non-demented Parkison´s patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000; 123: 340-352.

  39. Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Menthis MJ et al. Metabolic correlates of levodopa response in Parkison´s disease. Neurology 2001; 57: 2083-8.

  40. Salmon E, Van der Linden MV, Franck G. Anterior cingulated and motor network metabolic impairment in progressive supranuclear palsy. Neuroimage 1997; 5: 173-178.

  41. Hamaguchi T, KitaNoto T, Sato T, Nizusawa H, Nakamura Y et al. Clinical diagnosis of MN2-pipe sporadic Creutzfeldt-Jakob disease. Neurology 2005; 64: 643-48.

  42. Cardoso F, Setti K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol 2006; 5: 589-602.

  43. Kulh DE, Phelps ME, Markham CH et al. Cerebral metabolism and atrophy in Huntington´s disease determined by F-18-FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-34.

  44. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L et al. Brain white Matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 2006; 47: 215-22.

  45. Mazziotta JC, Phelps ME, Pahl JJ et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington´s disease. N Engl J Med 1987; 316: 357-362.

  46. Rottenberg DA, Moeller JR, Strother SC et al. The metabolic pathology of AIDS dementia complex. Ann Neurol 1987; 22: 700-706.

  47. Liow J, Rehm K, Strother SC, Anderson JR, Morch N et al. Comparison of voxel and volume of interest based analyses of FDG PET SCAN of HIV positive and healthy individuals. J Nucl Med 2000; 41: 612-21.

  48. Nobler MS, Pelton GH, Sackeim HA. Cerebral blood flow and metabolism in late-life depression and dementia. J Geriatr Psychiatry Neurol 1999; 12: 118-127.

  49. Jagust WJ, Friendland RP, Budinger TF. Positron emission tomography differentiates normal pressure hydrocephalus from Alzheimer´s disease. J Neurol Neurosurg Psychiatr 1985; 48: 10916.

  50. Kessler RM, Parker ES, Clark CS et al. Regional cerebral glucose metabolism in patients with alcoholic Korsakoff syndrome. Soc Neurosci 1984; 10: 541.




2020     |     www.medigraphic.com